ZIOPHARM Oncology Inc. (ZIOP)

Oncology Corporate Profile

Stock Performance

8.0400
-0.0600

3 Month Stock History Chart

HQ Location

1180 Avenue of the Americas, Suite 2020
New York, NY 10036

Company Description

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.

Website: http://www.ziopharm.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Ad-RTS-hIL-12DNA-based therapeuticBreast cancerII
Ad-RTS-hIL-12DNA-based therapeuticGlioblastoma Multiforme (GBM)I
Ad-RTS-hIL-12 (+ veledimex)DNA-based therapeuticRecurrent Glioblastoma Multiforme (GBM)I

View additional information on product candidates here »

Source: http://www.ziopharm.com

Recent News Headlines

Ziopharm Breast Cancer Gene Therapy Tied to 'Higher Than Expected' Toxicity

10/11/2016 04:43 pm

(TheStreet) Oct 10, 2016 - Six of nine breast cancer patients treated with an experimental gene therapy from Ziopharm Oncology experienced a potentially dangerous immune system-related toxicity known as cytokine release syndrome.

ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

7/19/2016 12:08 pm

(ZIOPHARM) July 19, 2016 - ZIOPHARM Oncology, Inc. today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.

ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

7/15/2016 03:48 pm

(NASDAQ) July 15, 2016 - ZIOPHARM Oncology, Inc. today issued the following statement regarding the Company's ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma:

Brain Tumor Patient Dies After Ziopharm Gene Therapy Injection

7/15/2016 02:30 pm

(TheStreet) July 14, 2016 - The circumstances surrounding the Ziopharm patient deaths come amid heightened scrutiny of experimental anti-cancer therapies.

ZIOPHARM Announces Plans for Phase I Clinical Trial with CD33 CAR-T Cell Therapy Targeting Acute Myeloid Leukemia

7/12/2016 03:18 pm

(TheStreet) July 12, 2016 - ZIOPHARM Oncology, Inc. today announced plans for a Phase I adoptive cellular therapy clinical trial utilizing autologous T cells transduced with lentivirus to express a CD33-specific chimeric antigen receptor (CAR) in patients with relapsed or refractory acute myeloid leukemia (AML).

Ziopharm Co-Dependency Spirals Down in Amended Intrexon Deal

6/30/2016 05:22 pm

(TheStreet) June 30, 2016 - The amended agreement with Intrexon bolsters the bear argument against Ziopharm that its entire cancer drug pipeline is mediocre and overvalued.

AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

6/5/2016 06:02 pm

(NASDAQ) June 5, 2016 - Results of expansion cohort of open-label Phase 1 study found no dose-limiting toxicities and frequent, reversible eye toxicities; preliminary efficacy results showed an estimated 30 percent progression-free survival at six months; AbbVie will be advancing ABT-414 to a randomized Phase 2 clinical trial in patients with EGFR-amplified glioblastoma.

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

5/20/2016 04:48 pm

(TheStreet) May 20, 2016 - Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority owned by R.J. Kirk.

ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

5/19/2016 05:33 pm

(NASDAQ) May 18, 2016 - Data to be presented at the 2016 ASCO annual meeting; company to discuss results with regulators after additional follow up.

NCCN Melanoma Guideline Update: It's About Immunotherapy and Targeted Therapy

4/1/2016 11:01 am

(AJMC) Mar 31, 2016 - At the National Comprehensive Cancer Network 21st Annual Conference, John A. Thompson, MD, presented an update on where the field of melanoma treatment stands today.

Gov’t Panel Backs Drug For Delusions In Parkinson’s Patients

3/30/2016 12:02 pm

(Washington Post/Associated Press) Mar 29, 2016 - FDA will decide on whether to approve the antipsychotic pimavanserin by May 1.

21st Century Breach Prompts 3 Federal Class-Action Lawsuits

3/24/2016 11:03 am

(The News-Press [Ft. Myers, FL]) Mar 23, 2016 - Patients affected by a recent computer data breach at 21st Century Oncology have filed federal class-action lawsuits, claiming the Fort Myers-based cancer-care provider failed to adequately protect sensitive medical and personal information.

The Most Promising Cancer Therapy in Decades Is About to Get Better

3/4/2016 07:00 am

(The Atlantic) Mar 3, 2016 - The rise of immunotherapy has been one of the most startling and promising developments in cancer research for some time. After decades of false starts and dead ends, scientists have finally found effective ways of marshaling the immune system to destroy cancers.

ZIOPHARM Announces First Patient Treated in the Dose Escalation Portion of the Phase 1 Study of Ad-RTS-hIL-12 for Advanced Glioma

2/24/2016 05:56 pm

(StreetInsider) Feb 24, 2016 - ZIOPHARM Oncology, Inc. today announced that, following the successful completion of the initial dose cohort, the first patient has been dosed at the succeeding dose level in the Company’s ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant glioma.

ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies

2/9/2016 05:48 pm

(Yahoo! Finance) Feb 9, 2016 - ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on new cancer immunotherapies, today announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in patients with advance lymphoid malignancies.

Medication Shows Promise of Protecting Fertility and the Defense System During Chemotherapy

12/15/2015 10:05 am

(LA BioMed) Dec 14, 2015 - Researchers at Los Angeles Biomedical Research Institute (LA BioMed) and the University of Southern California found the potent humanin analogue (HNG) protected male germ cells, which are essential to fertility, and white blood cells, which are the soldiers in the body’s defense system, in cancer research models undergoing chemotherapy.

'Suicide Gene Therapy' Plus Radiation Fights Prostate Cancer: Study

12/15/2015 10:05 am

(U.S. News & World Report/HealthDay News) Dec 14, 2015 - A combination of "suicide gene therapy" and radiation is highly effective in treating prostate cancer, researchers say.

Researchers Take First Step In Precision Medicine For Penile Cancer

12/15/2015 10:05 am

(U-M CCC) Dec 15, 2015 - Defining the genomic landscape reveals similarities with other squamous cell cancers.

New Method Of Diagnosing Deadly Fungal Lung Infection In Leukemia Patients Discovered

12/15/2015 10:05 am

(UTMB) Dec 14, 2015 - A team of researchers have discovered a new way for early detection of a potentially deadly fungal infection in patients with suppressed immune systems such as those being treated for leukemia or who have had an organ transplant.

Precision Medicine Trials for Cancer: A New Era

12/15/2015 10:05 am

(NCI/Cancer Currents Blog) Dec 10, 2015 - In this post, Jeff Abrams, M.D., and Nita Seibel, M.D., of NCI's Division of Cancer Treatment and Diagnosis, discuss how precision medicine is influencing the design and conduct of NCI-supported clinical trials.

Pitt Study: New Model of Collaborative Cancer Research May Help Advance Precision Medicine Studies

12/15/2015 10:05 am

(UPMC) Dec 15, 2015 - A new system that facilitates data and biospecimen sharing among cancer centers may speed cancer research findings from the laboratory to patient care, according to a study led by researchers at the University of Pittsburgh School of Medicine. The study was published December 15 in Cancer Research, a journal of the American Association for Cancer Research.

The Academic Difference

12/15/2015 10:05 am

(The Cancer Letter) Dec 11, 2015 - Academic cancer centers have a major and unique role to play in enhancing cancer research, clinical care and education. This role will increase in value as our understanding of the complexity of cancer grows and is applied to care of patients.

Burnout Affects About One in Three Gynecologic Oncologists

12/15/2015 10:05 am

(Physician’s Briefing/HealthDay News) Dec 14, 2015 - About one-third of gynecologic oncologists experience burnout, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

Review Explores Cancer Screening, Prevention, and Treatment in People with Mental Illness

12/15/2015 10:05 am

(American Cancer Society) Dec 11, 2015 - A new report calls attention to cancer in people with mental illness, suggesting that healthcare system and societal factors are just as critical as individual lifestyle factors— linked to smoking and obesity—that lead to health disparities among this group. The report appears early online in CA: A Cancer Journal for Clinicians.

Medicare's Bundled Payment Loses Some Interest Among Providers

12/15/2015 10:05 am

(Forbes) Dec 15, 2015 - Some 1,500 medical care providers are moving forward to accept bundled payments from the Medicare health insurance program for the elderly, but that’s just 25 percent of those that first expressed interest in a voluntary effort, a new analysis by health research firm Avalere Health shows.

AstraZeneca Explores Potential Deal With Acerta for Cancer Drug

12/15/2015 10:04 am

(Bloomberg) Dec 14, 2015 - AstraZeneca Plc said it’s exploring a deal with Acerta Pharma BV that would give the U.K. drugmaker a potential blockbuster medicine for blood cancers as well as diseases in which the body attacks itself.

Amgen Takes Back Three Drugs From GSK

12/15/2015 10:04 am

(PharmaTimes [UK]) Dec 15, 2015 - Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to bone drugs Prolia (denosumab) and Xgeva (denosumab) and cancer therapy Vectibix (panitumumab) in 48 countries around the globe.

Pregnancy Does Not Increase Risk of Hodgkin Lymphoma Relapse

12/15/2015 10:04 am

(ASCO) Dec 14, 2015 - Women who become pregnant while in remission from Hodgkin lymphoma are not at increased risk for cancer relapse, according to a Swedish study published on December 14 in the Journal of Clinical Oncology.

Five Factors Identify Subset of Patients With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab Treatment

12/15/2015 10:04 am

(AACR) Dec 15, 2015 - Patients with advanced cervical cancer who were at intermediate and high risk of poor outcome, as assessed by the Moore criteria, gained survival benefit from having bevacizumab added to their chemotherapy regimen while those at low risk of poor outcome did not, according to results of a major objective of the phase III NRG Oncology-Gynecologic Oncology Group protocol 240 (GOG 240) clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Expensive, Exploratory Research Biopsies Overused In Early Studies Of New Cancer Drugs

12/15/2015 10:04 am

(University of Chicago) Dec 14, 2015 - A study by University of Chicago cancer specialists shows that this costly, sometimes risky, and often painful process has had no impact on subsequent drug development or how physicians use these new drugs to treat future patients.

ZIOPHARM Announces Presentation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients With Locally Advanced or Metastatic Breast Cancer at 2015 SABCS

12/10/2015 06:06 pm

(TheStreet) Dec 10, 2015 - ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on new cancer immunotherapies, today announced the presentation of the study design and a trial update for a Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer.

Intrexon, Ziopharm Oncology to Pursue Immunotherapies for Graft-versus-Host Disease

9/29/2015 04:16 pm

(Genetic Engineering News) Sept 29, 2015 - Intrexon is joining forces with Ziopharm Oncology in a collaboration that will concentrate on the treatment and prevention of graft-versus-host disease (GvHD).

Ad Hoc: Biofrontera AG - FDA Accepts Filing of Ameluz® and BF-RhodoLED® Application

9/14/2015 11:01 am

(Benzinga) Sept 11, 2015 - Biofrontera AG, the biopharmaceutical company focusing on sun-induced skin cancer, has today been informed that the Food and Drug Administration (FDA), the responsible US government agency, has accepted filing of the New Drug Application (NDA) of Biofrontera's anti-skin cancer drug Ameluz® combined with the PDT lamp BF-RhodoLED®.

American Society of Hematology Awards Bridge Grants to Help Sustain Blood Disease Research

8/18/2015 12:01 pm

(ASH) Aug 18, 2015 - The American Society of Hematology, the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the 13 investigators who will receive ASH Bridge Grants for promising blood disease research that could otherwise not be funded by the National Institutes of Health as a result of severe federal funding restrictions.

ZIOPHARM Announces Orphan Drug Designation for Ad-RTS-hIL-12 in the Treatment of Malignant Glioma

7/27/2015 04:58 pm

(StreetInsider) July 24, 2015 - ZIOPHARM Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant glioma. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response.

The Project Data Sphere® initiative Achieves 1st Year Milestones

5/11/2015 12:00 pm

(Bloomberg) May 11, 2015 - Cancer community broadly shares, integrates, and analyzes clinical trial data within a single research platform to advance innovation and improve lives.

ZIOPHARM Announces Initiation of Phase 1 Study of Ad-RTS-IL-12 Gene Therapy in Patients With Brain Cancer

5/5/2015 04:53 pm

(TheStreet) May 5, 2015 - ZIOPHARM Oncology, Inc. today announced the initiation of a Phase 1 study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma or Grade III malignant glioma, a form of brain cancer.

ZIOPHARM Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients With Locally Advanced or Metastatic Breast Cancer

4/27/2015 04:10 pm

(Yahoo! News) Apr 27, 2015 - ZIOPHARM Oncology, Inc. today announced the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer.

Amgen's Cancer Immunotherapy Fails to Impress FDA Staff Reviewers

4/27/2015 10:04 am

(Reuters) Apr 27, 2015 - U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study.

Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm

4/2/2015 05:02 pm

(TheStreet) Apr 2, 2015 - Welcome to the pre-Passover/Easter Biotech Stock Mailbag. May you get your fill of matzoh and Peeps this weekend.

ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono

3/30/2015 05:10 pm

(Yahoo! Finance) Mar 30, 2015 - ZIOPHARM Oncology, Inc. and Intrexon Corporation today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany.

Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact

1/14/2015 06:06 pm

(NASDAQ) Jan 13, 2015 - Intrexon Corporation and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

High-Tech Goggles Help Surgeons Visualize Tumors

11/14/2014 05:04 am

(Medscape Medical News) Nov 13, 2014 - Augmented reality, a Google Glass–like technology, could help surgeons prepare to resect tumors, report researchers here at the American College of Surgeons 2014 Clinical Congress.